SCHEMBL20647932

SCHEMBL20647932

CCC(CC)COC(=O)[C@H](C)NP(=O)(OCC1O[C@@](C=NC)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ KRAS P01116 1/20 0.32
▸ BTN3A1 O00481 4/20 0.32
▸ POLRMT O00411 1/20 0.32
▸ RIPK1 Q13546 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19223302 1.00 CYP3A4 (0.35) CYP3A4CYP2C9KRASBTN3A1POLRMT
SCHEMBL18636581 1.00 CYP3A4 (0.35) CYP3A4CYP2C9KRASBTN3A1POLRMT
SCHEMBL18636579 1.00 CYP3A4 (0.35) CYP3A4CYP2C9KRASBTN3A1POLRMT
SCHEMBL23034636 1.00 CYP3A4 (0.35) CYP3A4CYP2C9KRASBTN3A1POLRMT
SCHEMBL18636388 1.00 CYP3A4 (0.35) CYP3A4CYP2C9KRASBTN3A1POLRMT
SCHEMBL23685889 1.00 CYP3A4 (0.35) CYP3A4CYP2C9KRASBTN3A1POLRMT
SCHEMBL19223102 1.00 CYP3A4 (0.35) CYP3A4CYP2C9KRASBTN3A1POLRMT
SCHEMBL18636609 1.00 CYP3A4 (0.35) CYP3A4CYP2C9KRASBTN3A1POLRMT
SCHEMBL21283656 0.94 CYP3A4 (0.37) CYP3A4CYP2C9BTN3A1POLRMT
SCHEMBL22142954 0.94 CYP3A4 (0.37) CYP3A4CYP2C9BTN3A1POLRMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024341-A1 INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS GILEAD SCIENCES, INC. 2024-01-25 — — US disclosed
US-20230027727-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-01-26 — — US disclosed
US-11382926-B2 Methods for treating Arenaviridae and Coronaviridae virus infections GILEAD SCIENCES, INC. (US) 2022-07-12 — — US disclosed
US-20220175805-A1 REMDESIVIR TREATMENT METHODS GILEAD SCIENCES, INC. 2022-06-09 — — US disclosed
US-11266666-B2 Methods for treating Filoviridae virus infections GILEAD SCIENCES, INC. (US) 2022-03-08 — — US disclosed
US-20210393659-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2021-12-23 — — US disclosed
US-20210052613-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2021-02-25 — — US disclosed
US-10695361-B2 Methods for treating arenaviridae and coronaviridae virus infections GILEAD SCIENCES, INC. (US) 2020-06-30 — — US disclosed
US-20190255085-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2019-08-22 — — US disclosed
WO-2019014247-A1 COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2019-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175805-A1 REMDESIVIR TREATMENT METHODS EIF2AK2, MTAP, ACE CYP3A4 628/4885CYP2C9 879/4885KRAS 1899/4885
US-10695361-B2 Methods for treating arenaviridae and coronaviridae virus infections ACE, PNP, ACE2 CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885
US-11382926-B2 Methods for treating Arenaviridae and Coronaviridae virus infections ACE, PNP, ACE2 CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885
US-20190255085-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS ACE, PNP, ACE2 CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885
US-20210393659-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS ACE, PNP, ACE2 CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885
US-20210052613-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS PNP, PRPF4, RPIA CYP3A4 772/4885CYP2C9 2974/4885KRAS 4427/4885
US-20240024341-A1 INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS SLC29A1, SLC28A1, RNMT CYP3A4 1076/4885CYP2C9 651/4885KRAS 2406/4885
US-20230027727-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS PNP, ACE, ACE2 CYP3A4 1181/4885CYP2C9 2188/4885KRAS 3790/4885
US-11266666-B2 Methods for treating Filoviridae virus infections PNP, PRPF4, RPIA CYP3A4 772/4885CYP2C9 2974/4885KRAS 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback